The Centers for Disease Control and Prevention (CDC) is doing research to determine whether or if there is a connection between two new vaccines against respiratory syncytial virus (RSV) and an uncommon condition of the brain system that affects older persons in the United States.
More than twenty occurrences of Guillain-Barre syndrome (GBS), a disorder that causes muscle weakness and paralysis, have been reported among the more than 9.5 million individuals who have received the immunizations. This information is the basis for the investigation. The number of instances is more than anticipated, but it is not sufficient to demonstrate a causative connection, according to those in charge of health.
At a meeting of an expert panel that provides the Centers for Disease Control and Prevention with advice on vaccine policy, the data was presented. In the previous year, the panel suggested that those aged 60 and older in the United States receive a single dose of the RSV vaccine, which may be either Abrysvo by Pfizer or Arexvy by GSK. In newborns and the elderly, the respiratory syncytial virus (RSV) is a common virus that can cause serious respiratory disease.
When compared to the projected rate of two cases per million, the majority of the GBS infections occurred among those who received the Pfizer vaccination. It was found that there were 4.6 cases per million of these individuals. The GSK vaccine resulted in a decreased incidence of new cases of GBS. A similar pattern of GBS cases was also documented by the Food and Drug Administration of the United States among individuals who had received the RSV vaccine.
Vaccine safety official at the Centers for Disease Control and Prevention (CDC) Dr. Tom Shimabukuro stated that the statistics indicate a possible elevated risk of GBS in RSV vaccine recipients aged 60 and older, which requires additional investigation. He advised individuals to discuss the vaccination with their primary care physicians before receiving it.
In a statement, representatives from both Pfizer and GSK stated that they were undertaking studies to determine the likelihood of GBS being caused by vaccines and monitoring the safety of their respective vaccines. According to them, the safety signal was complicated and might be affected by a variety of different characteristics.
Officials from the Centers for Disease Control and Prevention (CDC) have stated that the immunizations have avoided thousands of hospitalizations and hundreds of fatalities caused by RSV. They also stated that the advantages of vaccination outweigh the potential hazards.
The Science and Educational Media Group of the Howard Hughes Medical Institute provides financial assistance to the Health and Science Department of the Associated Press to fund its operations. All content is entirely the responsibility of the Associated Press.
